CA2607021A1 - Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih - Google Patents

Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih Download PDF

Info

Publication number
CA2607021A1
CA2607021A1 CA002607021A CA2607021A CA2607021A1 CA 2607021 A1 CA2607021 A1 CA 2607021A1 CA 002607021 A CA002607021 A CA 002607021A CA 2607021 A CA2607021 A CA 2607021A CA 2607021 A1 CA2607021 A1 CA 2607021A1
Authority
CA
Canada
Prior art keywords
phenyl
chcn
cyclopropyl
benzyl
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002607021A
Other languages
English (en)
Other versions
CA2607021C (fr
Inventor
Jean Luc Girardet
Yung-Hyo Koh
Stephanie Shaw
Hong Woo Kim
Zhi Hong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ardea Biociences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2607021A1 publication Critical patent/CA2607021A1/fr
Application granted granted Critical
Publication of CA2607021C publication Critical patent/CA2607021C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/28—Oxygen atom
    • C07D473/30—Oxygen atom attached in position 6, e.g. hypoxanthine

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA2607021A 2005-05-05 2006-05-05 Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih Expired - Fee Related CA2607021C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67866705P 2005-05-05 2005-05-05
US60/678,667 2005-05-05
PCT/US2006/017677 WO2006122003A2 (fr) 2005-05-05 2006-05-05 Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih

Publications (2)

Publication Number Publication Date
CA2607021A1 true CA2607021A1 (fr) 2006-11-16
CA2607021C CA2607021C (fr) 2013-10-29

Family

ID=37397195

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2607021A Expired - Fee Related CA2607021C (fr) 2005-05-05 2006-05-05 Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih

Country Status (12)

Country Link
US (2) US8227601B2 (fr)
EP (1) EP1877411B9 (fr)
JP (2) JP5138585B2 (fr)
CN (1) CN101233135B (fr)
AT (1) ATE541848T1 (fr)
AU (1) AU2006244195B2 (fr)
BR (1) BRPI0611455A2 (fr)
CA (1) CA2607021C (fr)
ES (1) ES2380951T3 (fr)
MX (1) MX2007013715A (fr)
WO (1) WO2006122003A2 (fr)
ZA (1) ZA200709481B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004274185B2 (en) * 2003-09-25 2009-12-10 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
WO2006122003A2 (fr) 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih
CA2673965A1 (fr) * 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Compose pyrazolopyridimidine
EP2220091B1 (fr) 2007-12-14 2012-07-25 Ardea Biosciences, Inc. Inhibiteurs de transcriptase inverse
EP2247591A1 (fr) 2008-02-06 2010-11-10 Novartis AG Pyrrolo [2,3-d]pyridines et leur utilisation comme inhibiteurs de tyrosin kinase
WO2010111406A2 (fr) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Composés et leurs utilisations thérapeutiques
KR102311234B1 (ko) * 2013-06-27 2021-10-12 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 바이러스 감염 및 기타 질환의 치료를 위한 피롤로[3,2-d]피리미딘 유도체
PE20170008A1 (es) 2014-04-25 2017-03-17 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1
US10913744B2 (en) 2015-02-13 2021-02-09 Dana-Farber Cancer Institute, Inc. LRRK2 inhibitors and methods of making and using the same
CN106188060A (zh) * 2015-04-29 2016-12-07 厦门大学 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用
KR102048719B1 (ko) * 2015-08-13 2019-11-26 베이징 한미 파마슈티컬 컴퍼니 리미티드 Irak4억제제 및 이의 용도
CN106117242B (zh) * 2016-06-27 2018-08-03 山东大学 四氢噻喃并嘧啶类衍生物及其制备方法与应用
CN107793417B (zh) * 2016-09-05 2020-06-09 复旦大学 吡咯并[2,3-d]嘧啶类化合物及其盐，及制备方法和药用用途
CN106749266B (zh) * 2016-11-14 2019-01-22 山东大学 吡咯并[2,3-d]嘧啶类化合物的高效制备方法
WO2022011171A1 (fr) * 2020-07-08 2022-01-13 Klotho Therapeutics, Inc. Nouveaux composés et méthodes permettant d'augmenter l'expression du gène klotho
TW201945003A (zh) 2018-03-01 2019-12-01 愛爾蘭商健生科學愛爾蘭無限公司 ２，４－二胺基喹唑啉衍生物及其醫學用途
CN111499639B (zh) * 2019-01-31 2022-03-04 四川大学华西医院 嘧啶酮衍生物及其在制药中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ229453A (en) * 1988-06-10 1991-08-27 Univ Minnesota & Southern Rese A pharmaceutical composition containing purine derivatives with nucleosides such as azt, as antiviral agents
WO2000027850A2 (fr) 1998-11-12 2000-05-18 Neurocrine Biosciences, Inc. Antagonistes de recepteurs du crf et methodes associees
US6414147B1 (en) * 1998-12-23 2002-07-02 Neurogen Corporation 2-amino-9-alkylpurines: GABA brain receptor ligands
CZ27399A3 (cs) 1999-01-26 2000-08-16 Ústav Experimentální Botaniky Av Čr Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv
YU25500A (sh) * 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
MXPA05008364A (es) 2003-02-07 2005-11-04 Janssen Pharmaceutica Nv Derivados de pirimidina para la prevencion de una infeccion por vih.
AU2004274185B2 (en) * 2003-09-25 2009-12-10 Janssen Pharmaceutica N.V. HIV replication inhibiting purine derivatives
EP1807430B1 (fr) 2004-10-29 2014-07-23 Janssen R&D Ireland Derives de pyrimidine bicycliques inhibant le vih
WO2006122003A2 (fr) * 2005-05-05 2006-11-16 Ardea Biosciences, Inc. Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih

Also Published As

Publication number Publication date
AU2006244195A1 (en) 2006-11-16
US20120226037A1 (en) 2012-09-06
EP1877411B9 (fr) 2012-08-29
ES2380951T3 (es) 2012-05-21
ATE541848T1 (de) 2012-02-15
CA2607021C (fr) 2013-10-29
EP1877411B1 (fr) 2012-01-18
JP2012188454A (ja) 2012-10-04
AU2006244195B2 (en) 2012-03-15
WO2006122003A3 (fr) 2007-01-04
JP5138585B2 (ja) 2013-02-06
US8354532B2 (en) 2013-01-15
ZA200709481B (en) 2008-11-26
ES2380951T9 (es) 2012-12-21
EP1877411A4 (fr) 2008-10-22
EP1877411A2 (fr) 2008-01-16
CN101233135B (zh) 2012-10-03
US20090124802A1 (en) 2009-05-14
JP2008540454A (ja) 2008-11-20
BRPI0611455A2 (pt) 2010-09-08
MX2007013715A (es) 2008-01-28
WO2006122003A2 (fr) 2006-11-16
US8227601B2 (en) 2012-07-24
CN101233135A (zh) 2008-07-30

Similar Documents

Publication Publication Date Title
CA2607021A1 (fr) Diaryl-purine, -azapurines et -deazapurines inhibiteurs non nucleosidiques de la transcriptase inverse utilises dans le traitement du vih
AU2010202750B2 (en) Novel heterocyclic compounds as HSP90-inhibitors
Ajani et al. Exploration of the chemistry and biological properties of pyrimidine as a privilege pharmacophore in therapeutics
Baraldi et al. Synthesis of new pyrazolo [4, 3-e]-1, 2, 4-triazolo [1, 5-c] pyrimidines and related heterocycles
Li et al. Synthesis and Anti‐tumor Activities of Novel Pyrazolo [1, 5‐a] pyrimidines
Singh et al. An exhaustive compilation on chemistry of triazolopyrimidine: A journey through decades
Dolzhenko et al. Synthesis of 5, 7-Diamino [1, 2, 4] triazolo [1, 2-a][1, 3, 5] triazines via Annulation of 1, 3, 5-Triazine Ring onto 3 (5)-Amino-1, 2, 4-trizoles
AU2011232841B2 (en) Purine compounds
Wippich et al. Regioselective Preparation of 1-(Bromomethyl)-5H-thiazolo [3, 2-a] quinazolin-5-ones and Analogous 5H-Thieno [3, 2-e] thiazolo [3, 2-a] pyrimidin-5-ones from Fused 2-(Alkenylthio) pyrimidin-4-ones
Al-Thebeiti Synthesis of some new thiazolo [3, 2-a] pyridines and related heterocyclic systems
Dolzhenko et al. Practical synthesis of regioisomeric 5 (7)-amino-6, 7 (4, 5)-dihydro [1, 2, 4] triazolo [1, 5-a][1, 3, 5] triazines
Al-Afaleq Heterocyclic synthesis via enaminonitriles: an efficient, one step synthesis of some novel azolo [1, 5-α] pyrimidine, pyrimido [1, 2-α]-benzimidazole, pyrido [1, 2-α] benzimidazole pyrimidine and pyrazole derivatives
Nassar et al. Synthesis, reactivity and antitumor activity of some new pyrazolo [3, 4-d] pyrimidine and their triazole derivatives
Refat et al. Synthesis and cytotoxicity activity of some novel hydrazide, pyrazole, isoxazole, pyrimidine and fused pyran-2-one derivatives
Elkhawaga et al. Synthesis of Some Imidazopyrazolopyrimidines, Pyrazolopyrimidopyrimidines and Pyrazolopyrimidothiazines.
AU2012203082A1 (en) Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of HIV
El-Badawi et al. Synthesis and Biological Evaluation of Some Novel N, N′-Bis-(1, 2, 4-Triazin-4-Yl) Dicarboxylic Acid Amides and Some Fused Rings with 1, 2, 4-Triazine Ring
Babkov et al. Methods for the synthesis of aza (deaza) xanthines as a basis of biologically active compounds
Al-Otaibi et al. Design, Synthesis and Biological Evaluation of Pyrido [2, 3-d] Pyrimidine Derivatives as Potential Anticancer Agents
Gatta et al. New [f]‐fused xanthines: Synthesis of 1, 3‐dipropyl‐1H, 3H‐pyrazino, pyrido, pyrimido and pyrrolo [2, 1‐f] purine‐2, 4‐diones
Yuyrova et al. Reaction of functionalized xanthinepyrimidines with benzyl (β-oxyethyl) hydrazines
Reddy et al. Synthesis of Novel (S)-Imidazolo [1, 2c][1, 2, 3] triazolo-[4, 5e] pyrimidine Derivatives
Sanemitsu et al. 1, 2, 4‐triazines. 7. Regioselective n2‐amination of 3‐methylthio‐1, 2, 4‐triazin‐5 (2H)‐ones. A novel synthesis of [1, 2, 4] triazolo [2, 3‐b][1, 2, 4] triazinones and‐triazine
Bakavolia et al. Reaction of ethyl 3-aminothieno [2, 3-b] pyridine-2-carboxylate: Synthesis of new functionalized thieno [2, 3-b] pyridine, pyrido [3', 2': 4, 5] thieno [3, 2-d][1, 3] thiazine and pyrido [3', 2': 4, 5] thieno [3, 2-d] pyrimidines
Abdel-Megid et al. Synthesis and Mollucicidal Activity of Some New Bicyclic and Polycyclic Pyrimidine Derivatives

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20210505